Arboretum Ventures

Convergent Dental Reaches 2,000 Solea Dental Lasers Across North America! “Our 2,000th installation is a testament to the trust and enthusiasm the dental community has for Solea,” said Convergent Dental CEO, Robert L. Gershon. “From solo practitioners to dental service organizations (DSOs) to dental schools, dental professionals are embracing Solea to improve patient experience, clinical effectiveness, practice efficiency, and procedural expansion.” #solea #solealaser #teamsolea #soleanation #pressrelease

Our very own Associate, James Kim, is the latest #VentureFellow at the Michigan Venture Capital Association (MVCA). James is already making a meaningful impact at Arboretum Ventures, where he’s involved in due diligence for potential new investments and providing valuable support to our current portfolio companies.

🚨 Big news from Francis Medical! 🚨 We’re thrilled to announce the successful close of an $80M Series C equity financing round! ✨ The financing was led by Arboretum Ventures and Solas BioVentures, with support from new investors Orlando Health Ventures and two strategic partners, as well as returning investors Coloplast A/S and Tonkawa. This funding will propel us toward: ✔️ Continuing our #VAPOR2 pivotal clinical study for #ProstateCancer ✔️ U.S. commercialization of #Vanquish, our groundbreaking water vapor ablation therapy, by late 2025 Vanquish is designed to use our breakthrough #WaterVaporTechnology to target cancerous prostate tissue while sparing healthy structures. This is a significant step in our mission to transform the treatment of prostate cancer and improve the lives of patients worldwide. 👏 A heartfelt thank you to our investors and partners for believing in our vision. Together, we’re changing the future of cancer care. Read the press release at: https://lnkd.in/giBnat_H Stay tuned for more updates as we continue this journey!

We are delighted to share results from the First-In-Human trial of the Reprieve System, unveiled at the CSI Focus D-HF conference in Frankfurt! These findings demonstrate the Reprieve System’s potential to enable safe, rapid, and effective decongestion for heart failure patients while protecting kidney function. 🙏 A special thank you to Dr. Piotr Ponikowski for his work on this study and for presenting these exciting results. Your expertise and insights are invaluable as we work together to redefine care for heart failure patients. 🌟 Looking ahead to early 2025, we are focused on building clinical momentum with the upcoming results from the FASTR U.S. Pilot and the launch of the FASTR II Global Pivotal Study! Read more in our latest press release: https://lnkd.in/gfN_pKvg CSI congress #CSIFocusDHF #HeartFailure #Innovation #ClinicalTrials #MedicalDevices #HealthTech

Arboretum would like to extend a warm and enthusiastic welcome to Jason as the new CEO of Avation Medical. We are thrilled to have you on board and are confident that your leadership, vision, and experience will play a pivotal role in driving the next chapter of growth and success for the company.

Congratulations to Reprieve Cardiovascular on their nomination for the Emerging MedTech Company of the Year Award!

🎉 Congratulations to Flosonics on winning the 2024 Digital Health Hub Foundation Award in the Best in Class – Provider Diagnostic category! 🌟 Cheers to your continued success and innovation! 🎊

Tim Petersen Receives Induction into the Michigan Venture Capital Association Hall of Fame at the 17th Annual Awards Event https://lnkd.in/g3FDww56

Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™, Co-Led by Arboretum Ventures and Johnson & Johnson Innovation https://lnkd.in/egYV5Kbs

We are excited to announce the completion of enrollment in the "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. The FASTR trial aims to compare the effectiveness of decongestive therapy administered by the Reprieve System with Optimal Diuretic Therapy in patients diagnosed with acute decompensated heart failure. Completing enrollment in the FASTR trial marks a significant milestone for Reprieve as we advance our mission to improve the lives of patients living with heart failure. Go here to learn more: https://lnkd.in/ehrB84_U